Pfizer Inc, Shanghai Fosun Pharmaceutical(Group)Co., Ltd., Novo Nordisk A/S are dominating the China Injectable Drug Delivery Devices Market in 2019

China Injectable Drug Delivery Devices Market is expected to grow at a healthy CAGR of 17.5% in the forecast period 2020 to 2027. The years considered for study are as mentioned below.

Access full report @

China injectable drug delivery devices market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments in expanding their production facility for manufacturing of different injectable drug delivery devices along with various acquisitions and partnership to enter in specific market which have led the manufacturers to established their foot prints.

The major players dealing in China injectable drug delivery devices market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio and has taken various strategic decisions to expand their business. For instance, in August 2018, Pfizer Inc. has entered in a contract with Antares Pharma to develop a self-administered auto-injector for an undisclosed drug with an investment of USD 465.00 million in their new sterile injectables plant. In this contract, Pfizer Inc. has paid for the product advancement as well as it was responsible for getting FDA approval whereas Antares Pharma has offered its QuickShot auto-injector. This has helped the company to provide its new product in the market.

Pfizer Inc. is the dominating player in the China injectable drug delivery devices market. The other key players existing in the market includes Baxter, BD, Changee Medical Devices Co., Ltd, China Meheco Group Co., Ltd, Elcam Medical, Eli Lilly and Company, Gerresheimer AG, Harbin Pharmaceutical Group Co., Ltd, Jiangsu Delfu Medical Device Co., Ltd, Mylan N.V., Novo Nordisk A/S, Sandoz International GmbH (a subsidiary of Novartis AG), Sanofi, Schott AG, Shanghai Fosun Pharmaceutical(Group)Co., Ltd, Shanghai General Pharmaceutical Co., Ltd, Terumo Corporation, West Pharmaceutical Services, Inc, YPSOMED, Shanghai Umitai Medical Technology Co.,Ltd., Hengrui Medicine among others.

China Injectable Drug Delivery Devices MarketPfizer Inc.:

Pfizer Inc. was founded in 1849 and headquartered in New York, U.S. The company is engaged in discovering, developing and, manufacturing of healthcare products. The company operates through two segments, named as Innovative Health (IH) and Essential Health (EH). The company's IH segment concentrates on creating and commercializing immunizations and prescriptions that enhance patients' lives, and in addition products for the end user health care. Its therapeutic regions incorporate oncology, antibodies, cardiovascular, metabolic, irritation, immunology, neuroscience, torment, uncommon illnesses and purchaser human services. The company's EH portion incorporates legacy brands that have lost or will soon lose market superiority in both rising and developed markets, biosimilar marked generics, generic sterile injectable products and mixture frameworks. EH segment additionally incorporates another EH innovative work association, and additionally contract manufacturing business. The products offered by the company related to the market are abboject, ansyr & ansyr II, add-vantage, carpuject, isecure, act-o-vial, cytosafe, oncotain, in which market focused products are abboject, ansyr & ansyr II, add-vantage, carpuject and isecure.

For instance,

  • In July 2019, Mylan N.V. and Upjohn and a division of Pfizer Inc. have announced their definitive agreement to establish a new pharmaceutical giant company for global and Chinese market. Through the agreement, the companies will bring their specialized therapeutics in more than 165 markets to expand their presence of generic products in the market.

The company has its geographic presence in more than 40 countries across North America, South America, Europe, Middle East, Africa, and Asia-Pacific. The subsidiaries of the company include Agouron Pharmaceuticals (U.S.), AHP Holdings B.V. (Netherlands), Alacer Corp. (U.S.), Alpharma Pharmaceuticals LLC (U.S.), Bioren, LLC (U.S.) and G. D. Searle & Co. Limited (U.K.) among others.

Shanghai Fosun PharmaceuticalGroupCo., Ltd.:

Shanghai Fosun Pharmaceutical(Group)Co., Ltd. headquartered in Shanghai, China was founded in 1994. The company deals in different business segments including pharmaceutical manufacturing and R&D, healthcare services, medical devices and medical diagnosis, among which the market focused segment is pharmaceutical manufacturing. The company offers various products in local market including pharma products, medical diagnostics products and medical devices and healthcare services in which Pharma Products is the market focused category

The company has wide presence in China with number of subsidiaries such as Yao pharma (China), Wanbang pharma (China), Aohong pharma (China) and Chancheng Hospital Sisram Medical (China) among others.

Novo Nordisk A/S:

Novo Nordisk A/S was founded in 1989 and headquartered in Bagsvaerd, Denmark. Novo Nordisk A/S is a global healthcare company engaged in diabetes care and manufacturing of pharmaceutical products. The company operates through two business segments, diabetes and obesity care and biopharmaceuticals in which diabetes and obesity is the market focused segment. The diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The products offered by the company related to the market are diabetes delivery systems, diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy among which diabetes delivery systems is the market focused category.

For instance,

  • In December 2019, Novo Nordisk A/S launched injectable insulin in China, which was previously approved in more than 29 countries and overseas. The company claims that, the injectable insulin would be the best to secrete the insulin in human bodies. The launch of the product has helped the company to reach out in Chinese local market for the treatment of diabetes.

The company has wide global presence across North America, Europe, Latin America, Middle East and Africa and Asia-Pacific. Some of its subsidiaries include Novo Nordisk Pharma Argentina S.A., (Argentina), Novo Nordisk Producao Farmacêutica do Brasil Ltda. (Brazil), Novo Nordisk Farmaceutica do Brasil Ltda. (Brazil), Novo Nordisk Farmaceutica Limitada (Chile), Novo Nordisk Colombia SAS (Colombia) among others.